GlassScriptPhysician profile
Ali Kazemi
NPI 1609019520
$12,237.71
in general payments reported to CMS, 2019-2025
31 companies · $3,324 in 2025
The $3,324 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $307 · 2021: $255 · 2022: $1,615 · 2023: $2,404 · 2024: $3,978 · 2025: $3,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,675 · Travel and Lodging: $1,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,675.42 |
| Travel and Lodging | $1,030.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,610.18 | 2020-2025 | |
| Boston Scientific Corporation | $1,648.20 | 2019-2024 | Apollo Esg System |
| Janssen Biotech, INC. | $1,101.82 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,094.92 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Ardelyx, INC. | $816.35 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $777.45 | 2023-2025 | Voquezna |
| Pfizer INC. | $531.75 | 2022-2025 | |
| Qol Medical, LLC | $444.23 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $341.80 | 2022-2025 | Entyvio |
| Genzyme Corporation | $302.20 | 2022-2025 | |
| Celgene Corporation | $300.37 | 2022-2024 | Zeposia, Zerit |
| Lilly USA, LLC | $296.82 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Regeneron Healthcare Solutions, INC. | $267.11 | 2022-2025 | Dupixent |
| Novo Nordisk INC | $232.64 | 2023-2025 | Wegovy |
| Medtronic, INC. | $190.39 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $164.66 | 2020-2024 | Linzess |
| Madrigal Pharmaceuticals | $133.81 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $128.00 | 2023-2024 | Dificid |
| Apollo Endosurgery US INC | $114.79 | 2023 | Overstitch Endoscopic Suturing System |
| Ferring Pharmaceuticals INC. | $111.44 | 2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $105.77 | 2023 | Zeposia |
| Gilead Sciences, INC. | $98.36 | 2023-2025 | |
| Daiichi Sankyo INC. | $84.80 | 2024-2025 | Injectafer |
| Braintree Laboratories, INC. | $69.76 | 2020-2023 | Sutab |
| Lucid Diagnostics INC. | $61.88 | 2025 | |
| Redhill Biopharma INC. | $45.34 | 2021 | |
| Intercept Pharmaceuticals, INC. | $45.16 | 2023-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $41.87 | 2025 | Zenpep |
| Endogastric Solutions, INC | $41.44 | 2022-2024 | Esophyx |
| Shionogi INC | $23.05 | 2020 | |
| Allergan, INC. | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Kazemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.